Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence - sprookjes - yvandenbroek - TriplyDB

Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence

Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence

http://www.wikidata.org/entity/Q24601034

about

Brain Insulin Resistance at the Crossroads of Metabolic and Cognitive Disorders in Humans The Rationale for Insulin Therapy in Alzheimer's Disease Current Research Therapeutic Strategies for Alzheimer's Disease Treatment Obesity Reduces Cognitive and Motor Functions across the Lifespan Metabolic Risk Factors of Sporadic Alzheimer's Disease: Implications in the Pathology, Pathogenesis and Treatment Intranasal insulin therapy for cognitive impairment and neurodegeneration: current state of the art Insulin regulates brain function, but how does it get there?Elevated risk of type 2 diabetes for development of Alzheimer disease: a key role for oxidative stress in brain Brain insulin resistance in Alzheimer's disease and its potential treatment with GLP-1 analogs Aberrant insulin signaling in Alzheimer's disease: current knowledge High-fat diet impairs spatial memory and hippocampal intrinsic excitability and sex-dependently alters circulating insulin and hippocampal insulin sensitivity A new brain drug delivery strategy: focused ultrasound-enhanced intranasal drug delivery Finding needles in a haystack: application of network analysis and target enrichment studies for the identification of potential anti-diabetic phytochemicals Insulin Regulates the Activity of the High-Affinity Choline Transporter CHT Pathophysiologic relationship between Alzheimer's disease, cerebrovascular disease, and cardiovascular risk: A review and synthesis Central Nervous Insulin Administration before Nocturnal Sleep Decreases Breakfast Intake in Healthy Young and Elderly Subjects.Slow gait speed - an indicator of lower cerebral vasoreactivity in type 2 diabetes mellitus Unraveling Alzheimer's: Making Sense of the Relationship between Diabetes and Alzheimer's Disease1 Involvement of the Bradykinin B1 Receptor in Microglial Activation: In Vitro and In Vivo Studies.The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer's disease.Treadmill exercise alleviates impairment of spatial learning ability through enhancing cell proliferation in the streptozotocin-induced Alzheimer's disease rats.Agile delivery of protein therapeutics to CNS The effect of insulin and insulin-like growth factors on hippocampus- and amygdala-dependent long-term memory formation Functional MRI signal fluctuations: a preclinical biomarker for cognitive impairment in type 2 diabetes?Enhanced memory consolidation in mice lacking the circadian modulators Sharp1 and -2 caused by elevated Igf2 signaling in the cortex.Moving beyond anti-amyloid therapy for the prevention and treatment of Alzheimer's disease.Nasal NSAIDs for Alzheimer's Disease.Sweet taste receptor signaling network: possible implication for cognitive functioning.Intranasal insulin enhanced resting-state functional connectivity of hippocampal regions in type 2 diabetes.Patients lacking sustainable long-term weight loss after gastric bypass surgery show signs of decreased inhibitory control of prepotent responses Brain Uptake of Neurotherapeutics after Intranasal versus Intraperitoneal Delivery in Mice.Hippocampal Insulin Resistance Impairs Spatial Learning and Synaptic Plasticity.Intranasal Insulin Improves Age-Related Cognitive Deficits and Reverses Electrophysiological Correlates of Brain Aging Intranasal insulin protects against substantia nigra dopaminergic neuronal loss and alleviates motor deficits induced by 6-OHDA in rats Recent Developments in Understanding Brain Aging: Implications for Alzheimer's Disease and Vascular Cognitive Impairment.Intranasal Insulin and Insulin-Like Growth Factor 1 as Neuroprotectants in Acute Ischemic Stroke.Blood glucose levels and cortical thinning in cognitively normal, middle-aged adults In Alzheimer's Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial.Recurrent Sleep Fragmentation Induces Insulin and Neuroprotective Mechanisms in Middle-Aged Flies.Relationships between diabetes and cognitive impairment

P2860

Q26739671-4843D047-9FBB-435C-9C01-1557D6CB568E Q26744834-C2AB04B7-6943-4B10-B41C-5E33D1C2F879 Q26765530-EBFAF658-EDB1-4F86-9D52-D79C44F161BF Q26765753-05A72391-CA10-48AA-AB2B-0F98A8A4E57E Q26799893-AA67D712-7C72-4235-B53D-F8556809DF7A Q26830845-AEE920CA-0229-4BFF-8677-8416586BBA3B Q27001988-3A68F150-2447-480A-A73A-E0107477215B Q27003253-6EE4F3BD-BD83-4D92-A9B9-BF91A773DC9A Q27012801-7400957F-DE66-4994-96DD-1ECE76239721 Q27024222-00B6348A-B175-47DB-B8BA-3CD6CC287F41 Q27321647-A3875884-7412-4F05-9B83-FA7722B04DD3 Q28543529-9894EE59-050E-492A-8939-937F4CB3B071 Q28544976-89BBB990-C345-492D-AB57-DCCD7A352FAD Q28546435-461DE0FD-28BE-4FB8-B323-8A55FCE8CEDD Q30235369-E854ABB3-C55F-49A6-93DD-A92C5599C5D4 Q30837838-74C14236-B4B4-424A-B99E-9F94F0683619 Q33164505-5F260DD8-D4B6-4F03-AAC2-E190EFAFF31D Q33362745-94E5A68C-6784-4038-BD9E-1BA4CB457BF8 Q33577362-DC0AED39-2550-47E0-A623-0DC2A8AF808C Q33600053-DDCD9E09-29F4-4C89-89F1-48746B1505E5 Q33629864-0E119FD2-21A7-4135-B1BA-61D545B901E5 Q34079647-15FBA442-CFA3-4D5E-82AC-3B32C6BB67D2 Q34245876-6DCD8769-FD98-4F2A-B335-FFBC7C40E717 Q34263961-5BC5B8BA-77F8-4A69-AC2E-AE0531530063 Q34481910-D1808BC0-6F75-4879-8008-5EF75B39D481 Q34538592-C9D78993-D256-4D0A-8E1B-F95D94B3B246 Q34658846-01394711-C9CE-4A42-8EA5-96CF88F807C3 Q35012275-02B3F24D-24F4-4ADC-902D-77B63D5D0928 Q35114494-0B8BF583-794A-47C9-BE16-8919AD28103F Q35182241-6F21E7ED-2472-4701-8CAB-B65211DAF3A3 Q36052412-118F45AC-0BB5-4372-98A8-521A8655ED41 Q36186276-D121A42D-9BC8-4DCA-8B80-AA4C51F89C51 Q36444567-B2A6358C-5982-49A2-AAC7-97490010F76E Q36578704-A0D8D0A0-26B0-42A3-952B-444DEAE3921A Q36853502-01534199-868C-4DDE-A33D-77A52CF7476D Q36883430-F440A9F8-6566-42DD-8E86-712CE8C9C210 Q36926947-81B24287-1CED-45A8-BEC0-DDDC96DF6066 Q36928283-8CA8BD28-6E12-4DE8-809C-21668762271F Q37143865-200AFE15-5BAD-4B83-9264-35FE068AD7FB Q37162219-A2ED0616-9767-4CAD-B21B-811552DDD9AA

P2860

Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence

http://www.wikidata.org/entity/Q24601034

description

2013 nî lūn-bûn

@nan

2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Intranasal insulin as a treatm ...... research and clinical evidence

@ast

Intranasal insulin as a treatm ...... research and clinical evidence

@en

Intranasal insulin as a treatm ...... research and clinical evidence

@nl

type

label

Intranasal insulin as a treatm ...... research and clinical evidence

@ast

Intranasal insulin as a treatm ...... research and clinical evidence

@en

Intranasal insulin as a treatm ...... research and clinical evidence

@nl

prefLabel

Intranasal insulin as a treatm ...... research and clinical evidence

@ast

Intranasal insulin as a treatm ...... research and clinical evidence

@en

Intranasal insulin as a treatm ...... research and clinical evidence

@nl

P1433

Q24601034-B731B205-5C10-4B18-AEC0-947A4D7890DB

P1476

Q24601034-E0AA3562-F8CC-4334-87A3-E825606A0803

P2093

Q24601034-401FEF6A-1828-4FA7-AB1D-271C2C8F603D

Q24601034-6AA15D87-3D55-4C93-ADA1-D526A9B8B18D

Q24601034-7DF14E29-7482-4995-9F7F-40DA7ED4BFEC

Q24601034-A19456B3-B32A-492F-8EE8-EA2CBDAF877D

Q24601034-A8F9689F-BE71-45D6-A251-29A918C86DFB

Q24601034-DF9083C1-FEAB-4DE2-9869-47EB5AFF6206

P2860

Q24601034-006939A8-3F59-45B3-8598-77116E3574E8

Q24601034-00E9AF3A-F0E2-4C6D-9D4D-F0EC78A882F3

Q24601034-06DFAE98-8951-4F62-B966-21709D7F387E

Q24601034-09A1CC6B-9C3A-4D91-A220-6D6964146DCB

Q24601034-0DD383CB-6CB9-4F1A-9AE0-03A340947849

Q24601034-18EC78F7-F787-4716-BD2E-41828EF8ABFD

Q24601034-19087750-983E-41F5-86C4-521C82497EFC

Q24601034-24942CBE-0820-4C4D-91A4-191B8DD4031D

Q24601034-285D07FF-B512-46D7-8DDE-86C95D001DD8

Q24601034-2894BCA2-EB75-437D-A1FC-5278B3935BB1

P2888

Q24601034-2947C0B5-BE64-4A28-B6DE-BD4E4F6907C8

P304

Q24601034-5B6C1818-0617-452B-AF3F-A802B9B751A0

P31

Q24601034-5E325ACF-EC8C-4AC7-9EF4-CA989EF943DE

Q24601034-A164CECF-2E21-4E08-8630-444DF4718003

P3181

Q24601034-85FA2AAE-C540-485A-83ED-3FEAA285A171

P356

Q24601034-DD009D3B-5DCB-486B-A6AA-3194D55F483C

P407

Q24601034-F4963BE5-E70C-4D22-87EA-944D16AF2617

P433

Q24601034-18BE1829-936F-434B-97B4-9B6E913E16B1

P478

Q24601034-EF21E7CB-E356-4278-9E29-520CA318ADD2

P50

Q24601034-136FA636-998E-4E3D-BFFC-6B5E20323C43

Q24601034-20152FE5-2760-4CAC-B117-3B7D930D8B92

Q24601034-7F727FAC-A4D5-4561-BA39-E4AAD80D9A94

P577

Q24601034-1B9C1C67-BED7-4EF0-80B8-DF1DFB58A88A

Q24601034-EEFF2BA5-5C61-4E53-842E-AA1E7A6FBD65

P5875

Q24601034-6EDDC2FF-DEF7-4398-BA91-887264C5BB42

P6179

Q24601034-81479F92-0303-4E6E-A7E6-29C9E0471406

P698

Q24601034-EF12F667-2700-4CE7-98DD-6F03FA2A538F

P921

Q24601034-A7C485E0-BD89-465D-9D41-9D11B7C34451

Q24601034-C138B1E8-BBDE-4BB2-A876-A9D0F1CD6BCF

Q24601034-E0F02B5E-9C6A-4003-89A1-902BE9E25C58

Q24601034-F2FF585B-65E7-4381-87BF-8DC9962D84B0

Q24601034-F8D5ED9C-1CFE-482E-935D-47971F328070

P932

Q24601034-7A84C466-21A0-41E0-91F5-A821E2802578

P3181

P356

S40263-013-0076-8

P1433

P1476

Intranasal insulin as a treatm ...... research and clinical evidence

@en

P2093

Colin D Chapman

http://www.w3.org/2001/XMLSchema#string

Fernanda G De Felice

http://www.w3.org/2001/XMLSchema#string

Manfred Hallschmid

http://www.w3.org/2001/XMLSchema#string

Suzanne Craft

http://www.w3.org/2001/XMLSchema#string

William H Frey

http://www.w3.org/2001/XMLSchema#string

Yvonne F Brünner

http://www.w3.org/2001/XMLSchema#string

P2860

Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease

Neural correlates of Alzheimer's disease and mild cognitive impairment: a systematic and quantitative meta-analysis involving 1351 patients

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

Global prevalence of dementia: a Delphi consensus study

Intranasal insulin enhances postprandial thermogenesis and lowers postprandial serum insulin levels in healthy men

Alzheimer's disease and insulin resistance: translating basic science into clinical applications

Neuropathological stageing of Alzheimer-related changes

Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease

Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers

Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling

P2888

s40263-013-0076-8

P304

505-14

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1394111

http://www.w3.org/2001/XMLSchema#string

P356

10.1007/S40263-013-0076-8

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

Christian Hölscher

Jessica Freiherr

Christian Benedict

P577

2013-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236967928

http://www.w3.org/2001/XMLSchema#string

P6179

1049364511

http://www.w3.org/2001/XMLSchema#string

P698

23719722

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

3709085

http://www.w3.org/2001/XMLSchema#string